Fundraising Fox
Vida Ventures
Venture capitalActively deployingLos Angeles · Pre-Seed–Late Stage · 42 people tracked
Also known as VIDA · VIDA VENTURES ADVISORS, LLC · VIDA VENTURES MANAGEMENT CO. LLC · Vida Wealth Partners, Inc.
Find your way into Vida Ventures
86 people in our graph share verified history with the Vida Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Vida Ventures invests in biomedical innovation with the goal of advancing breakthrough science into therapies that make a meaningful difference for patients. The firm emphasizes company creation and value realization in the therapeutics space, backing novel drug programs across areas such as genetic medicines and immunology. Its approach is grounded in core values including patient focus, integrity, entrepreneurship, boldness, humility, collaboration, and flexibility, reflecting a partnership-driven model that supports founders in turning cutting-edge science into clinical-stage medicines.
Source: firm website, verified Sep 29, 2026.
Team · 42 people
from the firm's website & curated & public directories
Founder mafia
The Vida Ventures mafia →7 people who came through Vida Ventures went on to found or lead other companies.
What they invest in
from 43 of 56 portfolio companiesBiotech ×41Healthtech ×22Medical Devices ×17Deep Tech ×10AI & Machine Learning ×7Digital Health ×6Consumer ×1Direct to Consumer ×1
HQs:United States×41Denmark×1
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×72 founders×53 founders×14+ founders×2
Where their founders studiedfrom 11 founders with education data
Massachusetts Institute of Technology ×3Harvard Business School ×2Harvard University ×2
What their founders studiedfrom 10 founders with field-of-study data
Life Sciences ×8Medicine ×3Chemistry ×2
Where their founders worked beforefrom 12 founders with career history
MPM BioImpact ×2
Investments · 56 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 32024 · 82023 · 32022 · 32021 · 32020 · 52019 · 42018 · 22017 · 540 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Board seatHelen S. Kim· per SEC Form D
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
BoardNicholas G. Galakatos(Director)in
Board seatStefan Vitorovic· per SEC Form D
Co-investorsAvoro Capital AdvisorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstone+6 more
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene; former President and Chief Executive Officer)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer; one of the founders of Allogene)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsAvoro Capital AdvisorsForesite CapitalTPGGilead SciencesVVAG Special
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life Sciences+9 more
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsAtlas VentureMPM BioImpactForbionHercules Capital, Inc.RA Capital
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesWestlake Village BioPartnersGilead SciencesKleiner PerkinsOxford Finance LLCRTW Investments L.P.+1 more
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Co-investorsPivotal Life SciencesPontifax Venture CapitalTarnagulla VenturesTCG Crossover
Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.
BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
William J. Newell(Executive Officer, Director)Jane Chung(Chief Executive Officer)inHans-Peter Gerber(Chief Scientific Officer)inDavid Pauling(Chief Administrative Officer and General Counsel)inJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in
Co-investorsOwl CapitalSamsara BioCapitalSolasta VenturesSV Health Investors
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsYsios CapitalHealthCapJeito Capital
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+2 more
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
Co-investorsAtlas VentureLightspeed Venture PartnersOmega FundsTenmileAbingworthAlleyCorp+1 more
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)inAmanda J. Redig(Chief Medical Officer)inScott Lesley(President & CSO)inPamela Holland(SVP of Biology)inSally Johnson(Chief People Officer)in
Co-investorsMRL Ventures FundThe Column Group
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo Capital+8 more
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatHelen S. Kim· per SEC Form D
Co-investorsNextech InvestThe Column GroupSamsara BioCapital
ByHeart is an infant formula company that manufactures science-driven baby formula with its own manufacturing process and supply chain.
ConsumerDirect to ConsumerFoodTechHealthtechNew York, US
Mia B. Funt(Executive Officer, Director)inRon Belldegrun(Co-founder)inMia Funt(Founder)inMia(Co-founder)Georg Krause-Vilmar(Executive Officer)inNiall Mullane(Executive Officer)in
Board seatArie BelldegrunJoshua Kazam· per SEC Form D
Co-investorsEvolution VC PartnersOCV PartnersPolaris PartnersRed Sea Ventures
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
BiotechHealthtechNew York, US
Sean Algeo(Executive Officer, Promoter)inMark A. McCamish(Executive Officer, Director)inDavid M. Tanen(Executive Officer, Promoter)
BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in
Board seatHelen S. KimJoshua KazamArie Belldegrun· per SEC Form D
Co-investorsGV (Google Ventures)Nextech InvestWellington Management
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Board seatJoshua Kazam· per SEC Form D
Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech InvestBlackRockCommodore CapitalInvus+2 more
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Board seatRajul Jain· per SEC Form D
Co-investorsEcoR1 CapitalJeito CapitalTPG
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Board seatHelen S. Kim· per SEC Form D
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Board seatStefan Vitorovic· per SEC Form D
Co-investorsEcoR1 CapitalAlly Bridge GroupClarus VenturesPolaris PartnersSoleus Capital
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatStefan Vitorovic· per SEC Form D
Co-investorsAtlas VentureLightstone VenturesPivotal Life SciencesHatteras Venture PartnersLongwood Fund
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Board seatStefan Vitorovic· per SEC Form D
Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 CapitalCatalio Capital ManagementPolaris Partners
.jpeg){kind=logo}
Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.
BiotechHealthtechLongevity
Co-investorsAgent CapitalOlive Tree CapitalService Provider CapitalFred Hutchinson Cancer Research CenterHumboldtLeaps by Bayer
BiotechWatertown, US
Kathy Bergsteinsson(Executive Officer)inKathy Yi(Executive Officer)inJoseph Knowles(Executive Officer, Director)
BoardLucio Iannone(Director)inArjun Goyal(Director)Jill DeSimone(Director)
Co-investorsLeaps by Bayer
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestOrbiMedDigitalis VenturesNVIDIA
AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease.
BiotechDeep TechHealthtechDurham, US
Co-investorsColumbus Venture PartnersTPG
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesGoldman Sachs+1 more
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossoverThird Rock Ventures+1 more
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)inRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsFinchley Healthcare VenturesPfizer Venture InvestmentsRA CapitalSofinnova VenturesForbion
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalLifeSci Venture PartnersMedicxiOberland Capital+3 more
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsElm Street VenturesFrazier Life SciencesRA Capital+1 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyFidelity Investments+5 more
A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments.
BiotechHealthtechSan Francisco, US
Jeffrey Nau(Executive Officer, Director)inMark A. Murray(Executive Officer, Director)D. Michael Ackermann(Director)
BoardWilliam J Link(Director)Ali Behbahani(Director)in
Co-investorsFlying L PartnersNew Enterprise Associates (NEA)Versant Venture AIV HoldingsVersant Ventures
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsCurative VenturesForesite CapitalNextech InvestRidgeback CapitalThe Column Group
Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.
Biotech
Co-investorsRA CapitalSR One Capital Management
Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.
BiotechHealthtechMedical Devices
Co-investorsOak HC/FTOak Investment Partners
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpact+1 more
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardMaha Katabi(Director)inPerry Nisen(Executive Officer, Director)inMaria Fardis(Director)inRajul Jain(Director)in
Co-investorsFinchley Healthcare VenturesLongitude CapitalSofinnova VenturesBiotechnology Value FundFrazier Life Sciences
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestAbingworth+3 more
Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.
AI & Machine LearningBiotechDeep TechWatertown, US
Victor Kotelianski(Founder)Daniel Anderson(Founder and Director)Robert Langer(Founder)Marino Zerial(Founder)Brad Pentelute(Founder)Amir Nashat, ScD(Founder, Director and CEO)
Co-investorsLeaps by BayerBessemer Venture PartnersSafar PartnersPolaris Partners
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen Horowitzabrdn plcBiotechnology Value FundForesite CapitalHillhouse InvestmentOmega Funds+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Baby GenerationMeridianMade, Inc.ReWovenVeterinary PrimeVision PathAsklepios BioPharmaceuticalInnoskelLocanabioNASDAQ: ALLONASDAQ: CNTANASDAQ: DYNNASDAQ: KRONNASDAQ: KYTXNASDAQ: VIGLProtego
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 14
9 IPOs · 5 acquisitions · showing 11Aktis OncologyNASDAQ: AKTSPraxisNASDAQ: PRAXAllogene TherapeuticsNASDAQ: ALLOAvalyn Pharma IncNASDAQ: AVLNDyne TherapeuticsNASDAQ: DYNKyverna TherapeuticsNASDAQ: KYTXLB PharmaceuticalsNASDAQ: LBRXSutrobioNASDAQ: STRONASDAQ: KRONacq. by Concentra BiosciencesNASDAQ: VIGLacq. by SanofiPeloton Therapeuticsacq. by Merck
Portfolio news
latest coverage across their companiesSonoThera · finsmes.com · Jun 10, 2026
Third Arc Bio · finance.yahoo.com · Feb 4, 2026
Antares Therapeutics · finsmes.com · Jun 11, 2025
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Vida Ventures IILPs: The Regents of the University of California | 2019 | — | 2.1% | 1.08x | 0.63x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 6
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Kyverna Therapeutics | 11.1% | $22.00 | Feb 2024 | $99.5M |
| Dyne Therapeutics | 5.8% | $28.00 | Jan 2021 | $82.9M |
| Praxis | 6.7% | $18.25 | May 2021 | $53.6M |
| Avalyn Pharma Inc | 3.0% | $18.00 | Apr 2026 | $23M |
| Sutrobio | 4.1% | $15.00 | Sep 2018 | $13.9M |
| LB Pharmaceuticals | 2.5% | $15.00 | Sep 2025 | $8.3M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ1 insider ownership filing (Forms 3/4/5)
at LB PHARMACEUTICALS INC (LBRX)
Files 13F institutional holdings reports · latest Nov 2025
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Vida Ventures made?
- Vida Ventures has 56 tracked investments, 14 of which have exited, including 8 dated in the last 24 months.
- What stage does Vida Ventures invest at?
- Vida Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Vida Ventures focus on?
- Vida Ventures focuses on Biotech, Deep Tech, Healthtech, Longevity, Medical Devices.
- Where is Vida Ventures located?
- Vida Ventures is headquartered in Los Angeles, US.
- Does Vida Ventures lead rounds?
- Vida Ventures typically participates in rounds rather than leading them.
- Who does Vida Ventures co-invest with?
- Vida Ventures most often shares deals with EcoR1 Capital, Nextech Invest, RA Capital, among 66 tracked co-investors.
- What size deals does Vida Ventures back?
- Across 13 deals with disclosed amounts, Vida Ventures has joined rounds of $50M – $410M (median $130M).
Co-investors · 20
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Pontifax is a venture capital firm focused on life sciences and healthcare technologies, investing across all development stages from early-stage startups to clinical-stage growth companies.
▶8 more co-investors
HealthCapNew Enterprise Associates (NEA)General AtlanticJohnson & Johnson Innovation – JJDCYsios CapitalMedical Excellence CapitalVertex Ventures HCXtripe Angels
Firms observed investing alongside Vida Ventures, from public investor directories. Shared companies are the overlap with Vida Ventures's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Pontifax is a venture capital firm focused on life sciences and healthcare technologies, investing across all development stages from early-stage startups to clinical-stage growth companies.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Ahren Innovation Capital is a deep-tech investment firm that backs companies emerging at the intersection of breakthrough science and advanced technology, supported by science partners and strategic LP relationships.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.